How long does Zilucoplan usually need to be used continuously?

Zilucoplan (Zilucoplan) is a daily subcutaneous injection of complement C5 inhibitor, suitable for the treatment of adult patients with anti-acetylcholine receptor antibody-positive myasthenia gravis (AChR-Ab+ gMG; rare disease). This type of autoimmune disease usually manifests as progressive muscle weakness, especially affecting the eyes, face, limbs, swallowing and other functions, and requires long-term control of the inflammatory response. The treatment principle of Zilucoplan is similar to that of most autoimmune drugs, emphasizing continuous and long-term drug intervention to maintain symptom stability and functional improvement.

According to drug instructions and clinical application experience in European and American countries, the use of zeleptide generally does not have a strictly limited treatment endpoint, but requires continuous use under the evaluation of a professional doctor. Its daily dosing frequency is closely related to its pharmacokinetics. In order to maintain the continuous inhibition of the complement system, long-term administration is required. In addition, myasthenia gravis is a chronic immune disorder and is not reversible in the short term. Therefore, the therapeutic effect of Zilucoplan usually appears gradually after weeks or months, and maintaining the therapeutic effect also depends on regular medication.

There is currently no evidence to support a model of short-term use followed by discontinuation of treatment. If the patient achieves disease remission goals during use, the doctor may appropriately adjust the dose or evaluate the possibility of reducing the dose, but this is less common. Therefore, zeleptide is generally used clinically as part of a long-term maintenance treatment regimen.

In addition, patients need to receive regular assessments during the medication period, including myasthenia symptom scores, complement activity testing, infection risk monitoring, etc., so that the treatment plan can be adjusted individually. If a patient considers discontinuing medication due to adverse reactions, financial burden, or ineffective treatment, a professional doctor should also guide the transition or replacement of other targeted drugs. In general, the use cycle of zeleptide should be based on long-term, dynamic evaluation and not a one-time treatment plan.

Reference materials:https://www.drugs.com/zilucoplan.html